breast cancer

For the 19th year, DCI was local presenting sponsor for Komen NCTC's Triangle Race for the Cure, held Sept. 12. Team DCI raised spirits and funds.

Breast oncologist Carey Anders, MD, and young immunology researchers from Duke are among the featured speakers at the national Komen MBC webinar series.

The American Cancer Society hosts its first statewide North Carolina Breast Health Equity Summit on October 16. Registration is free.

This NIEHS WHA community talk, Oct. 8, will focus on how women of color can be empowered through knowledge about breast cancer.

Join Team DCI and turn your miles walked into dollars raised throughout the month of October, then join the virtual National Celebration on October 18.

Komen NCTC hosts its first annual gala to support metastatic breast cancer research; a virtual event with speakers, auctions, and treats on Saturday, October 10, at 7 p.m.

SAVE THE DATE: "What's Best For Breasts? A Conversation with Duke Clinicians" will be held online-only on Saturday, Sept. 19.

A new approach to training computational models on biological processes provides insights into how and why cancer cells metastasize to certain areas of the vasculature.

Duke Cancer Institute welcomes a new medical oncologist specializing in the treatment of breast cancer. He will practice at two of DCI's Wake County locations.

The Komen Triangle Race for the Cure on Saturday, September 12, is now virtual. Susan Dent, MD, FRCPC, MD, and Sarah Sammons, MD, are DCI's honorary team captains.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

On June 9, DCI and Susan G. Komen Triangle to Coast hosted "Navigating Survivorship,"a live patient forum on breast cancer and survivorship.

Carey Anders, MD, who completed a residency and fellowship at Duke, rounds out the leadership team at the Duke Center for Brain and Spine Metastasis

Lola Fayanju, MD, MA, MPHS, is determined to understand all of her patients as people.

Dr. Fayanju talks about some of the disparities we see in breast cancer, as well as some ways to ease stress and despair in these challenging times.

Flags were lowered to half-staff today across Duke for Neil Spector, MD, physician-scientist, mentor, advocate, friend, husband, and father who passed away on June 14.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

"It's my comfort spot. I can live my life when I’m here, even if I’m not feeling well, and they are always here to take care of me.”

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

The nine-woman APP team was awarded for their exceptional service to the Duke community during the 2018-2019 academic year.

Genetic testing at Duke revealed a devastating diagnosis for a young nurse. But she feels it also may have saved her life.

Duke Fencing students are asking the community to Fence4TheFight against breast cancer, in honor of their long-time manager Elizabeth Beguinet.

Dorothy Sipkins, MD, PhD, and P. Kelly Marcom, MD, are co-PIs on a Phase 1 clinical trial of a new drug for breast cancer patients whose disease has spread to the bone.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

Jennifer K. Plichta, MD, Assistant Professor of Surgery, Division of Surgical Oncology, on being appointed to the editorial board of Breast Cancer Research.

Lola Fayanju, MD, and her team will develop a prediction model to identify women with mutable risk factors for compromised breast cancer care.

Updated genetic screening guidelines published by NCCN feature emerging evidence on personalized medicine.

ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.

The mainstay drug trastuzumab could benefit from another antibody to remove roadblocks.

Duke Cancer Institute hosted its Sixth Annual Scientific Retreat on Friday, October 25; attracting 166 DCI physicians, researchers, staff, and guests.

What if beating breast cancer means weakening what beats in the chest?

Medical oncologist and cardio-oncology specialist Susan Dent, MD, FRCPC,is the editor of a new book Practical Cardio-Oncology (Oct. 16, 2019)

Drug shuts down a pathway tumor cells use to become resistant to hormone therapies in animal studies.

Randles' team is one of 15 investigator-led teams being given priority to run her cancer simulations on the nation's first exascale computer "Aurora."

For a sixth year, Duke Cancer Institute is teaming up in October with the American Cancer Society (ACS) as local presenting sponsor for Making Strides.

What's Best For Breasts?, A Conversation with Duke Clinicians, will be held at the Trent Semans Center Grand Hall from 8 a.m. to 3 p.m. on Saturday, Sept. 21.

Nancy Davenport-Ennis has survived cancer twice. One of her many strategies for thriving—look for ways to help others. Learn more about her patient advocacy.

Duke helps women understand their individual risk of breast cancer. The services mainly target women with a family history, genetic mutation, or abnormal breast biopsy.

For women with DCIS, researchers are using “machine learning” to reduce unnecessary follow-up breast imaging and offer some women less-invasive treatment options.